Michael Naso, PhD
FounderMichael Naso has worked for more than 30 years in pharma and biotech organizations toward the discover and movement into early development innovative therapeutics including antibodies, bispecific antibodies, cell and gene therapies. Michael contributed to the successful approval and marketing of Remicade, Simponi, Stelara, Tremfya, as well as numerous preclinical programs at Centocor and Janssen. Most recently, he helped found Century Therapeutics and built the research organization there that brought the first ever multiply precision engineered, iPSC derived cell therapy into the clinic for lymphoma and autoimmunity. Michael has extensive expertise in protein engineering, including regulatory submissions and patent filings. He has also served as an expert witness in legal matters
Hillary Quinn, MS
FounderHillary has over 20 years of experience in preclinical pharmacology across pharma and biotech, spanning Oncology, Immuno-Oncology, and Autoimmune diseases. She has advanced small molecules, biologics, and cell therapies from discovery through early clinical development and contributed to programs supporting the approvals of Siltuximab (SYLVANT), Golimumab (SIMPONI), Talazoparib/Niraparib (AKEEGA), Erdafitinib (BALVERSA), Daratumumab (DARZALEX), Amivantamab (RYBREVANT), and Epoetin alfa (PROCRIT) at Johnson & Johnson.
As an early leader at Century Therapeutics, she built Pharmacology and Cell Biology teams, defined preclinical strategies for precision-engineered iPSC-derived NK and γδ T-cell programs, and advanced CNTY-101 into the clinic.
Hillary leads end-to-end preclinical strategy across assay development, model selection, candidate profiling, and IND-enabling studies, with deep experience in complex in vivo models and diverse therapeutic modalities. She partners closely with Regulatory, Manufacturing, and Early Development teams, oversees CRO-led GLP studies, contributes to IND documentation, and has served on IACUC and ethics committees.